3 results
The purpose of this study is to allow collection of safety and tolerability data in subjects benefitting from treatment with spartalizumab as a single agent or in combination with other study treatments in a pre-defined (Appendix Section 16.1)…
Primary Objective: The primary objective of this study is to identify whether the Geko system can augment flow compared to IPCS in post-thrombotic limbs before after stenting.(group 1) In group 2 we want to identify whether the Geko with occluded…
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)